ROTI, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 1.198
EU - Europa 882
AS - Asia 365
SA - Sud America 6
AF - Africa 1
Totale 2.452
Nazione #
US - Stati Uniti d'America 1.192
IE - Irlanda 238
SE - Svezia 175
SG - Singapore 172
IT - Italia 161
HK - Hong Kong 74
UA - Ucraina 71
FI - Finlandia 67
VN - Vietnam 53
RU - Federazione Russa 47
CN - Cina 42
DE - Germania 26
GB - Regno Unito 25
RO - Romania 16
KR - Corea 12
FR - Francia 11
CH - Svizzera 9
NL - Olanda 8
BE - Belgio 7
BR - Brasile 6
CZ - Repubblica Ceca 6
PL - Polonia 6
AT - Austria 4
GR - Grecia 3
IL - Israele 3
MX - Messico 3
CA - Canada 2
LB - Libano 2
UZ - Uzbekistan 2
AM - Armenia 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
ES - Italia 1
GE - Georgia 1
IN - India 1
KG - Kirghizistan 1
LK - Sri Lanka 1
NI - Nicaragua 1
Totale 2.452
Città #
Chandler 248
Dublin 238
San Mateo 164
Singapore 131
Boardman 82
Hong Kong 74
Santa Clara 65
Ann Arbor 61
Altamura 57
Medford 55
Princeton 54
Dong Ket 53
Perugia 53
Wilmington 48
Lawrence 44
Andover 38
Jacksonville 37
Helsinki 18
Beijing 15
Saint Petersburg 15
Bucharest 14
Seoul 12
Ashburn 9
Woodbridge 9
Assisi 8
Brussels 7
Munich 7
Norwalk 7
Boston 6
Dearborn 6
Des Moines 6
Los Angeles 6
New York 6
Dallas 5
Bastia 4
Frankfurt Am Main 4
Houston 4
San Paolo di Civitate 4
Auburn Hills 3
Brno 3
Moscow 3
Tel Aviv 3
Den Haag 2
Falls Church 2
Foligno 2
Macerata 2
Melissa 2
Mexico City 2
Milan 2
Olomouc 2
Parma 2
Shanghai 2
Timisoara 2
West Jordan 2
Abidjan 1
Amsterdam 1
Birmingham 1
Bishkek 1
Cariacica 1
Castiglione del Lago 1
Colombo 1
Coroatá 1
Dnipro 1
Falkenstein 1
Guangzhou 1
Huskvarna 1
Madrid 1
Managua 1
Montreal 1
Nanjing 1
Napoli 1
Nuneaton 1
Nürnberg 1
Paris 1
Ponta Grossa 1
Redmond 1
Redwood City 1
Secaucus 1
Sombrio 1
Tbilisi 1
Toronto 1
Vienna 1
Yerevan 1
Totale 1.739
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 131
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 115
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 86
Acute lymphoblastic leukaemia in Noonan syndrome 84
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 78
Constitutive phosphorylation of Janus kinase2 in the GL15 glioblastoma derived human cell line 76
Genetic pathways in low-and high-grade HCV-related lymphomas are different 69
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 68
null 63
DHPLC analysis of NPM1 mutations in adult primary AML. 62
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia 60
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML) 60
Angiopoietins expression by human myeloma cells. 59
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 59
Different genomic imbalances in low- and high-grade HCV-related lymphomas 58
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 53
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 53
Quantitative detection of NPM1 mutations as marker of minimal residual disease (MRD) in the large majority of AML with normal karyotype 52
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 50
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes. 50
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 47
Denaturing high performance liquid chromatography analysis of npm1 mutations in adult primary acute myeloid leukemia. 45
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 44
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. 43
Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL 42
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement 42
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML). 41
Mutational analisys of JAK2 VAL617PHE in a new series of chronic myelomonocytic leukemia and related atypical myeloproliferative disorders 41
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 40
Il-7 is induced by il-6 in human myeloma cells: role in multiple myeloma. 39
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 39
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 38
Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. 37
Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies 37
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6. 36
Molecular cytogenetic studies of myelodysplastic/ myloproliferative disease. 36
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 35
NPM1 haploinsufficiency in MDS/AML with del(5q)/monosomy 5 34
Quantitative detection of NPM1 mutations as marker of minimal residual disease (MRD) in the large majority of AML with normal karyotype. 33
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma. 31
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 30
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. 29
Modulating Notch1 With Signature-based Small Molecule Library Screening 29
Multiple Myeloma Patient with unusual extramedullary involvement 29
Osteopontin is produced by human multiple myeloma cells. 28
Identification of AML1-ETO modulators by chemical genomics. 28
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: Potential relationship with myeloma-induced angiogenesis 25
NPM1 gene mutations in acute myeloid leukemia. 25
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. 25
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. 23
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML 22
NPM1 monoallelic deletion in a subgroup of MDS/AML with del(5q) or monosomy 5 and complex karyotype 22
Targeting NOTCH1 in hematopoietic malignancy. 22
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. 21
New Approaches to Target T-ALL 21
Genetic and proteomic approaches to identify cancer drug targets. 16
Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in Acute Myeloid Leukemia 2
Totale 2.563
Categoria #
all - tutte 13.145
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.145


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202056 0 0 0 0 0 0 0 5 14 19 4 14
2020/2021313 0 10 17 7 116 28 13 3 27 13 18 61
2021/2022527 9 115 11 30 24 3 1 158 7 22 71 76
2022/2023780 56 155 5 72 47 76 0 38 308 0 19 4
2023/2024312 27 26 20 12 2 3 63 0 19 10 44 86
2024/2025295 16 72 37 21 110 21 14 4 0 0 0 0
Totale 2.563